Important Announcement About ALOXI®

The Aloxi Patient Assistance Program (PAP) is no longer accepting new applications for assistance. Patients who contact the Eisai Assistance Program will be advised to discuss treatment options, including lower-cost alternatives, and other currently available patient support resources, with their prescribing physician.

Eisai Assistance Program

Eisai Reimbursement Services for ALOXI® will no longer be available after April 27, 2018. If you are a healthcare provider or office staff member and need assistance with reimbursement issues, please contact the patient’s health insurance provider.

Phone: 1-866-61- EISAI (1-866-613-4724) 
Monday – Friday, 8am – 8pm ET

Medical Information

For Medical Information or to report an Adverse Event or Product Complaint:

Phone: 855-541-3495 
Email: usmedinfo@helsinn.com

Patient Support Resources

These foundations offer financial and other assistance (education, counseling, support groups, etc.) to patients.


Assistance Fund (TAF)

www.theassistancefund.org >

CancerCare

www.cancercare.org >


Good Days at Chronic Disease Fund

www.gooddaysfromcdf.org >

HealthWell Foundations

www.healthwellfoundation.org >

Patient Access Network (PAN) Foundation

www.panfoundation.org >

Patient Advocate Foundation (PAF)

www.patientadvocate.org >

Additional Information

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

+ EXPAND- COLLAPSE

Indication in Adults

ALOXI® injection 0.25 mg/5ml is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Indication in Pediatrics

ALOXI® injection 20mcg/kg (max 1.5mg) is indicated in patients ≥ 1 month up to 17 years of age, for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.

Important Safety Information

Contraindications

  • ALOXI® is contraindicated in patients known to have hypersensitivity to the drug or any of its components
  • Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5-HT3 receptor antagonists
  • Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone, but particularly with the use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue ALOXI® and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if ALOXI® is used concomitantly with other serotonergic drugs 
  • Adverse Reactions

  • In adults, the most commonly reported adverse drug reactions include headache (9%) and constipation (5%)
  • In pediatric patients, while they require a higher dose of palonosetron, the safety profile is consistent with the established profile in adults; however, adverse reactions were reported in < 0.1% of pediatric patients
  •  

    For more information about ALOXI®, please see full Prescribing Information.